Milestone Pharmaceuticals (MIST) Reaches New 12-Month High Following Insider Buying Activity

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) shares hit a new 52-week high during trading on Wednesday after an insider bought additional shares in the company. The stock traded as high as $19.09 and last traded at $18.38, with a volume of 3298 shares changing hands. The stock had previously closed at $18.55.

Specifically, major shareholder Rtw Investments, Lp purchased 666,667 shares of Milestone Pharmaceuticals stock in a transaction dated Thursday, May 9th. The shares were purchased at an average price of $15.00 per share, with a total value of $10,000,005.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Holdings A/S Novo purchased 333,333 shares of Milestone Pharmaceuticals stock in a transaction dated Monday, May 13th. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $4,999,995.00. The disclosure for this purchase can be found here.

TRADEMARK VIOLATION NOTICE: “Milestone Pharmaceuticals (MIST) Reaches New 12-Month High Following Insider Buying Activity” was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://dakotafinancialnews.com/2019/05/15/milestone-pharmaceuticals-mist-reaches-new-12-month-high-following-insider-buying-activity.html.

About Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.

Featured Article: Overbought

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.